NCM · Biotechnology

MLTX (MLTX) Stock

$19.57 -1.58% NCM: MLTX Healthcare

Valuation

MetricValue
Price$19.57
Market Cap$1.62B
P/E Ratio-4.71
P/B Ratio4.03
P/S Ratio0.00
EPS (TTM)$-3.53
52-Week High$62.75
52-Week Low$5.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-74.67%
ROA-53.54%
ROCE-80.59%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.40
Current Ratio9.38

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-54.0M$-65.0M$-54.0M$-143.0M$-245.0M
Net Profit$-54.0M$-50.0M$-36.0M$-119.0M$-227.0M
EPS$-1.45$-2.20$-0.73$-1.89$-3.53
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$10.0M$77.0M$527.0M$478.0M$424.0M
Total Liabilities$21.0M$8.0M$13.0M$25.0M$120.0M
Cash$8.0M$40.0M$451.0M$180.0M$335.0M
Borrowings$15.0M$0$4.0M$3.0M$76.0M

Latest News

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears Stocktwits · Jul 13, 2026 MoonLake Immunotherapeutics' CFO Sells 39K Shares Motley Fool · Jul 3, 2026 MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa Insider Monkey · Jun 30, 2026 How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering Simply Wall St. · Jun 25, 2026 Why MoonLake Immunotherapeutics Stock Wilted on Wednesday Motley Fool · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-56.0M$-43.0M$-117.0M$-196.0M
Investing Cash Flow$0$-32.0M$-25.0M$-206.0M$203.0M
Financing Cash Flow$0$135.0M$-3.0M$-1.0M$0
Net Cash Flow$7.0M$31.0M$412.0M$-271.0M$154.0M
Free Cash Flow$-35.0M$-56.0M$-43.0M$-117.0M$-196.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-18.52%
Quick Ratio8.60
Interest Coverage-35.00
Return 1Y-65.27%
Return 3Y-64.13%
Return 5Y93.60%

Ownership

Insiders Held8.42%
Institutions Held78.26%
Institutions Float Held85.46%
Institutional HolderSharesReport Date
BVF Inc.16,001,2842026-03-31
Deep Track Capital, Lp6,408,8632026-03-31
Cormorant Asset Management, LP4,480,4332026-03-31
Janus Henderson Group PLC3,451,6282026-03-31
Shaw D.E. & Co., Inc.2,390,6612026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABSI $7.13 -5.69% -11.32 $1.21B 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
CTMX $3.37 +4.01% -24.27 $541.98M 0.00%
ERAS $17.72 -2.42% -23.45 $6.15B 0.00%
MBX $65.93 -0.80% -13.02 $3.14B 0.00%

About MLTX

MLTX is led by CEO Jorge Santos da Silva, employs 100 people, headquartered in CH, publicly traded since 2020.

MLTX stock trades at $19.57 with a market capitalization of $1.62B. The stock is valued at a price-to-earnings (P/E) ratio of -4.71, price-to-book of 4.03, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.95 and $62.75, and currently trades 68.8% below its 52-week high.

On profitability, MLTX generates a return on equity (ROE) of -74.67%, return on capital employed of -80.59%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides